安儿宁颗粒联合布地奈德混悬液治疗支气管肺炎患儿的疗效及对血清IGF-ⅡGM-CSF sIL-2R的影响

Curative Efficacy of Anerning Granules combined with Budesonide in treatment of Bronchopneumonia and Effects on Serum IGF-Ⅱ GM-CSF and sIL-2R levels

目的:探讨安儿宁颗粒联合布地奈德混悬液治疗支气管肺炎患儿的疗效及对血清胰岛素样生长因子(IGF-Ⅱ)、粒细胞-巨噬细胞集落刺激因子(GM-CSF)、可溶性白细胞介素-2受体(sIL-2R)的影响。方法:选择2015年3月至2018年3月我院接诊的90例支气管肺炎患儿作为本研究对象,通过简单随机数表法分为观察组44例,对照组46例,在常规治疗基础上,对照组给予布地奈德混悬液雾化治疗,观察组在对照组基础上,给予安儿宁颗粒治疗,均连续治疗7d。比较两组临床疗效、实验室指标、血清IGF-Ⅱ、GM-CSF、sIL-2R的变化及不良反应。结果:观察组临床疗效总有效率为93.18%,明显高于对照组的73.91%(P<0.05);观察组和对照组治疗后C反应蛋白(CRP)、白细胞计数(WBC)及血清IGF-Ⅱ、GM-CSF、sIL-2R比较差异具有统计学意义[(1.79±0.30) mg/L vs(5.11±0.31) mg/L,(5.49±1.14)×109L-1vs(7.26±1.52)×109L-1,(0.39±0.04) ng/m L vs(0.67±0.08) ng/m L,(0.43±0.05)μg/L vs(0.71±0.09)μg/L,(132.83±11.51) pg/m L vs(159.47±14.74) pg/m L](P <0.05);观察组发热、咳嗽、气促、肺部湿啰音消失时间均明显比对照组短[(2.89±0.30) d vs(4.11±0.47) d,(4.05±0.49) d vs(5.29±0.55) d,(3.48±0.37) d vs(4.82±0.48) d,(3.27±0.40) d vs(4.71±0.45) d](P <0.05);两组治疗期间均无明显不良反应。结论:在支气管肺炎患儿中使用安儿宁颗粒联合布地奈德混悬液效果显著,有助于降低血清IGF-Ⅱ、GM-CSF、sIL-2R的表达,促进疾病恢复,安全性高,值得应用推广。

Objective:To study the curative efficacy of anerning granules combined with budesonide in treatment of bronchopneumonia and effects on serum insulin-like growth factor(IGF)-II,granulocyte-macrophage colony-stimulating factor(GM-CSF)and Solubility interleukin-2 receptor(sIL-2R)levels.Methods:90 patients of bronchopneumonia who received therapy from March 2015 to March 2018 in our hospital were selected as research objects,according to the simple random number table,those patients were divided into the 44 cases of the observation group and the 46 cases of the control group,on the basis of routine treatment,the control group was treated with budesonide suspension,while the observation group was treated with anerning granules on the basis of the control group,they were treated continuously for 7 days.The clinical efficacy,the changes of the laboratory indexes,serum levels of IGF-II,GM-CSF,sIL-2R and adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 93.18%,which was significantly higher than that of the control group 73.91%(P<0.05); there were significant differences in C-reactive protein(CRP),white blood cell count(WBC),serum levels of IGF-II,GM-CSF and sIL-2R between the observation group and the control group after treatment[(1.79±0.30)mg/L vs(5.11±0.31)mg/L,(5.49±1.14)×10^9/L vs(7.26±1.52)×10^9/L,(0.39±0.04)ng/ml vs(0.67±0.08)ng/ml,(0.43±0.05)μg/L vs(0.71±0.09)μg/L,(132.83±11.51)pg/ml vs(159.47±14.74)pg/ml](P<0.05).The fever,cough,shortness of breath and lung rales disappeared times in the observation group were significantly shorter than that of the control group[(2.89±0.30)d vs(4.11±0.47)d,(4.05±0.49)d vs(5.29±0.55)d,(3.48±0.37)d vs(4.82±0.48)d,(3.27±0.40)d vs(4.71±0.45)d](P<0.05).There was no obvious adverse reaction in the two groups during treatment.Conclusion:In children with bronchial pneumonia,the use of Anerning Granule combined with budesonide suspension has a significant effect,which can help to reduce the expression of serum IGF-II,GM-CSF,sIL-2R,and promote the recovery of disease.It is safe and worthy of application and promotion.